DeepIntent receives patent for technology that enables marketers to reach specific patient populations in a HIPAA-compliant and privacy-friendly manner

DeepIntent receives patent for technology that enables marketers to reach specific patient populations in a HIPAA-compliant and privacy-friendly manner

NEW YORK, January 11, 2022 / PRNewswire / – DeepIntent, the leading healthcare advertising technology company designed to influence patient health and business outcomes, today announced that the United States Patent and Trademark Office has granted the company a patent for its Audiences modeled by patients a technology that enables pharmaceutical advertisers to reach an audience of highly qualified patients with speed and precision, while respecting confidentiality.

Using patented Patient Modeled Audiences technology, advertisers can use the industry’s most comprehensive real-world clinical data sets to increase audience quality and improve programmatic campaign performance. Patent positions DeepIntent as the only demand-side platform (DSP) that can use HIPAA-compliant Patient Modeled Audiences technology to determine the correlation between demographics and disease to create accurate, campaign-specific modeled audiences .

“Healthcare marketers looking to educate patients about new clinical trials and treatments, especially those with rare diseases, have had to cast a wide net to reach clinically relevant audiences because they did not have of a solution offering the scale and ineffectiveness of many existing solutions has led to wasted advertising dollars and missed opportunities to improve patient health, ”said the founder and CEO of DeepIntent. Chris Paquette. “Patient Modeled Audiences is breakthrough technology that unlocks the value of real-world health data to improve audience quality for programmatic campaigns. This represents a huge step forward in our mission to use data science to help marketers reach patients with information that can improve their quality of life. “

DeepIntent’s patented technology is just as successful in reaching a qualified patient audience for common conditions such as chronic obstructive pulmonary disease (COPD) and plaque psoriasis as it is for rare, low-incidence conditions with a fraction of the prevalence , such as multiple sclerosis and inherited diseases. Angioedema (HAE). The unique technology allows marketers to reach rare disease patients during the narrow critical window soon after diagnosis, increasing the likelihood of putting patients on treatment and on the path to well-being.

Patient-modeled audiences provide full transparency with visibility into model inputs, scores, and audience selection. It is also tightly integrated with DeepIntent’s DSP for streamlined, end-to-end programmatic activation, measurement and optimization across all devices and channels, including Smart TV.

Strengthening the growth and momentum of the company, this is the second patent that DeepIntent has been granted in six months. The company was recently obtained a patent for its DeepIntent Outcomes ™ technology, which optimizes live campaigns based on real clinical data to improve audience quality and script performance. Both solutions demonstrate DeepIntent’s mission to improve patient outcomes through the astute use of advertising, data science, and real-world clinical data. In addition, patient-modeled audiences have been recognized as one of the most innovative products of 2020 by PM360.

To learn more about DeepIntent and its innovative technology that powers highly targeted, HIPAA-compliant patient campaigns, visit www.deepintent.com/marketers/patients/.

About DeepIntent

DeepIntent is the industry leader in healthcare advertising with data-driven solutions designed for the future. Purposefully designed for healthcare marketers, DeepIntent’s platform has been proven to improve audience quality and script performance. It allows marketers to plan, activate, measure and optimize their campaigns within a single platform. Designed by former Memorial Sloan Kettering data scientists, DeepIntent empowers nine of the ten largest pharmaceutical companies and leading healthcare advertising agencies to improve patient outcomes through the astute use of advertising , data science and real health data. For more information, visit DeepIntent.com or find us on Twitter, Facebook or LinkedIn.

press contact
Finn Partners for DeepIntent
Mena Buscetto
[email protected]
860-326-1698

SOURCE DeepIntent

.

Leave a Comment

Your email address will not be published. Required fields are marked *